Cargando…

Advanced Coats' disease: Treating the effect before the cause

An 8-year-old child with Stage 3A Coats' disease and severe submacular lipid exudation was initially treated with intravitreal injections of bevacizumab followed by triamcinolone. The exudative retinal detachment was then treated by scleral buckling, cryotherapy of persistent telangiectasia, an...

Descripción completa

Detalles Bibliográficos
Autor principal: Shukla, Dhananjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905927/
https://www.ncbi.nlm.nih.gov/pubmed/36760929
http://dx.doi.org/10.4103/ojo.ojo_249_21
_version_ 1784883909633245184
author Shukla, Dhananjay
author_facet Shukla, Dhananjay
author_sort Shukla, Dhananjay
collection PubMed
description An 8-year-old child with Stage 3A Coats' disease and severe submacular lipid exudation was initially treated with intravitreal injections of bevacizumab followed by triamcinolone. The exudative retinal detachment was then treated by scleral buckling, cryotherapy of persistent telangiectasia, and subretinal fluid drainage. The residual telangiectasia on the reattached retina was finally ablated by photocoagulation. The patient had a near-total resolution of submacular hard exudates without macular fibrosis. The peripheral telangiectasia and exudative detachment also regressed, with the sustained recovery of excellent visual acuity.
format Online
Article
Text
id pubmed-9905927
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-99059272023-02-08 Advanced Coats' disease: Treating the effect before the cause Shukla, Dhananjay Oman J Ophthalmol Case Report An 8-year-old child with Stage 3A Coats' disease and severe submacular lipid exudation was initially treated with intravitreal injections of bevacizumab followed by triamcinolone. The exudative retinal detachment was then treated by scleral buckling, cryotherapy of persistent telangiectasia, and subretinal fluid drainage. The residual telangiectasia on the reattached retina was finally ablated by photocoagulation. The patient had a near-total resolution of submacular hard exudates without macular fibrosis. The peripheral telangiectasia and exudative detachment also regressed, with the sustained recovery of excellent visual acuity. Wolters Kluwer - Medknow 2022-11-02 /pmc/articles/PMC9905927/ /pubmed/36760929 http://dx.doi.org/10.4103/ojo.ojo_249_21 Text en Copyright: © 2022 Oman Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Shukla, Dhananjay
Advanced Coats' disease: Treating the effect before the cause
title Advanced Coats' disease: Treating the effect before the cause
title_full Advanced Coats' disease: Treating the effect before the cause
title_fullStr Advanced Coats' disease: Treating the effect before the cause
title_full_unstemmed Advanced Coats' disease: Treating the effect before the cause
title_short Advanced Coats' disease: Treating the effect before the cause
title_sort advanced coats' disease: treating the effect before the cause
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905927/
https://www.ncbi.nlm.nih.gov/pubmed/36760929
http://dx.doi.org/10.4103/ojo.ojo_249_21
work_keys_str_mv AT shukladhananjay advancedcoatsdiseasetreatingtheeffectbeforethecause